Open AccessAbstract CT154: An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and antitumor activity of once-daily oral treatment with EO1001, a novel irreversible pan-ErbB inhibitor with promising brain penetration, in patients with advanced cancer
Author(s) -
Jeffrey Bacha,
Dennis Brown,
Sarath Kanekal,
Ian C. T. Nisbet,
Neil Sankar,
Wang Shen,
Helen Wheeler,
Kathy Skoff,
Zhen Zhong Wang
Publication year - 2020
Publication title -
cancer research
Language(s) - English
Resource type - Conference proceedings
SCImago Journal Rank - 1.055
H-Index - 84
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/1538-7445.am2020-ct154
Subject(s) - erbb , medicine , tolerability , toxicity , pharmacokinetics , pharmacology , oncology , dosing , cancer , adverse effect